表紙
市場調査レポート

肺腺がん:パイプライン製品の分析

Lung Adenocarcinoma - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 251516
出版日 ページ情報 英文 132 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
肺腺がん:パイプライン製品の分析 Lung Adenocarcinoma - Pipeline Review, H2 2015
出版日: 2015年12月16日 ページ情報: 英文 132 Pages
概要

肺腺がんは、たいてい肺の外側部分にある細胞から始まり、症状が起きる・診断を受けるよりもずっと以前から存在してる可能性があります。症状には慢性の咳が含まれ、また喀血は疾病の後期段階まであまり見られないでしょう。腺がんの初期症状で見落とされるのは、疲労感、軽度の息切れ、または背中、肩、もしくは胸の痛みなどです。治療には化学療法と放射線療法が用いられます。

当レポートでは、世界における肺腺がん治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

肺腺がんの概要

治療薬の開発

  • 肺腺がん向けパイプライン製品:概要
  • 肺腺がん向けパイプライン製品:比較分析

肺腺がん:各企業で開発中の治療薬

肺腺がん:大学/研究機関で研究中の治療薬

肺腺がん:パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

肺腺がん:開発中の製品の一覧(企業別)

肺腺がん:研究中の製品の一覧(大学/研究機関別)

肺腺がんの開発に従事している企業

  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Merck & Co., Inc.
  • 武田薬品工業
  • Pfizer Inc.
  • Genmab A/S.
  • Immunomedics, Inc.
  • Quantum Pharmaceuticals
  • BioNumerik Pharmaceuticals, Inc.
  • Axelar AB.
  • VG Life Sciences, Inc.
  • Medisyn Technologies, Inc.
  • Vichem Chemie Research Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.

肺腺がん:治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ディメスナ
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • アファチニブ
  • ダコミチニブ
  • AXL-1717
  • vintafolide
  • CD40Lを阻害する転移性肺がん・肺線がん向け細胞治療
  • poziotinib
  • metformin + bevacizumab + carboplatin + paclitaxel
  • 転移性腺癌向け幹細胞治療
  • solitomab
  • SNX-5422
  • hydroxychloroquine + sorafenib tosylate
  • MT-477
  • Tylophorine Analogs、ほか

肺腺がん:パイプライン製品の最新動向

肺腺がん:開発が休止状態の製品

肺腺がん関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7456IDB

Summary

Global Markets Direct's, 'Lung Adenocarcinoma - Pipeline Review, H2 2015', provides an overview of the Lung Adenocarcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lung Adenocarcinoma Overview
  • Therapeutics Development
    • Pipeline Products for Lung Adenocarcinoma - Overview
    • Pipeline Products for Lung Adenocarcinoma - Comparative Analysis
  • Lung Adenocarcinoma - Therapeutics under Development by Companies
  • Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes
  • Lung Adenocarcinoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Lung Adenocarcinoma - Products under Development by Companies
  • Lung Adenocarcinoma - Products under Investigation by Universities/Institutes
  • Lung Adenocarcinoma - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Astex Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • AVEO Pharmaceuticals, Inc.
    • Axelar AB
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Eisai Co., Ltd.
    • Genentech, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Immunomedics, Inc.
    • Incyte Corporation
    • Johnson & Johnson
    • Morphotek, Inc.
    • Pfizer Inc.
    • Sanofi
    • VG Life Sciences, Inc.
    • Vichem Chemie Research Ltd.
  • Lung Adenocarcinoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-203 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AXL-1717 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-6738 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-1163877 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dacomitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DBPR-112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EB-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • farletuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hydroxychloroquine + sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-42756493 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenvatinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAG-Tn3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • poziotinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ruxolitinib phosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-408701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit EGFR for Non-Small Cell Lung Cancer and Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SNX-5422 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • solitomab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TdCyd - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAL-401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lung Adenocarcinoma - Recent Pipeline Updates
  • Lung Adenocarcinoma - Dormant Projects
  • Lung Adenocarcinoma - Product Development Milestones
    • Featured News & Press Releases
      • May 29, 2015: Spectrum Pharmaceuticals Highlights Abstract of Clinical Data For Poziotinib at the 2015 ASCO Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lung Adenocarcinoma, H2 2015
  • Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Lung Adenocarcinoma - Pipeline by Amgen Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by AstraZeneca Plc, H2 2015
  • Lung Adenocarcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Axelar AB, H2 2015
  • Lung Adenocarcinoma - Pipeline by Bayer AG, H2 2015
  • Lung Adenocarcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Lung Adenocarcinoma - Pipeline by Eisai Co., Ltd., H2 2015
  • Lung Adenocarcinoma - Pipeline by Genentech, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
  • Lung Adenocarcinoma - Pipeline by Immunomedics, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Incyte Corporation, H2 2015
  • Lung Adenocarcinoma - Pipeline by Johnson & Johnson, H2 2015
  • Lung Adenocarcinoma - Pipeline by Morphotek, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Pfizer Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Sanofi, H2 2015
  • Lung Adenocarcinoma - Pipeline by VG Life Sciences, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Vichem Chemie Research Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Lung Adenocarcinoma Therapeutics - Recent Pipeline Updates, H2 2015
  • Lung Adenocarcinoma - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Lung Adenocarcinoma, H2 2015
  • Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top